{
  "id": 14443424,
  "title": "Cantor Fitzgerald reiterates Anteris Technologies stock rating at Overweight",
  "url": "https://urgent.news/2026/10/14/cantor-fitzgerald-reiterates-anteris-technologies-stock-rating-at",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-14T12:12:44.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/cantor-fitzgerald-reiterates-anteris-technologies-stock-rating-at-overweight-93CH-4949105"
  },
  "original_language": "en",
  "account": "Cantor Fitzgerald has reaffirmed its Overweight rating and set a $15.00 price target on Anteris Technologies Global (NASDAQ:AVR) stock. The company's stock is currently trading at $6.45, which represents a 41% increase over the past year. Analysts have price targets ranging from $10 to $16. Anteris Technologies is a medical device company with a market capitalization of $628.83 million. In the last twelve months, the company generated $2.24 million in revenue.\n\nTo discuss its innovative product DurAVR, Anteris Technologies recently held a fireside chat with its Chief Medical Officer, Dr. Chris Meduri. During the discussion, Cantor Fitzgerald highlighted Dr. Meduri's clinical perspective, emphasizing that the rationale behind DurAVR comes from a surgeon who has implanted every commercially available valve. Dr. Meduri's opinions are grounded in the mechanics of the device rather than marketing claims. He explained that DurAVR functions differently in the body compared to other options on the market, which becomes increasingly significant as TAVR (Transcatheter Aortic Valve Replacement) is adopted by younger, healthier patients.\n\nFrom a financial standpoint, Anteris Technologies has more cash than debt on its balance sheet, providing the company with financial flexibility as it advances through clinical trials. However, InvestingPro analysis suggests that the stock might be overvalued at its current price level based on Fair Value metrics. Analysts project a substantial 276% revenue growth for the company this year.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Cantor Fitzgerald reiterates Overweight on CytomX stock, $12 target",
        "url": "https://urgent.news/2026/10/13/cantor-fitzgerald-reiterates-overweight-on-cytomx-stock-12-target",
        "published": "2026-10-13T12:17:09.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}